Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Lexeo Therapeutics to post earnings of ($0.32) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 9:30 AM ET.

Lexeo Therapeutics Trading Up 0.5%

NASDAQ:LXEO opened at $6.66 on Monday. The company has a market capitalization of $486.11 million, a P/E ratio of -2.47 and a beta of 1.78. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $10.99. The firm has a fifty day simple moving average of $7.35 and a 200-day simple moving average of $7.90.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. HC Wainwright reduced their target price on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Raymond James Financial assumed coverage on Lexeo Therapeutics in a report on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 price objective on the stock. Oppenheimer restated an “outperform” rating and issued a $20.00 price objective on shares of Lexeo Therapeutics in a research note on Wednesday, December 10th. Cantor Fitzgerald initiated coverage on Lexeo Therapeutics in a report on Monday, December 1st. They set an “overweight” rating and a $19.00 target price for the company. Finally, Chardan Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Lexeo Therapeutics has an average rating of “Moderate Buy” and an average target price of $19.00.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 10,173 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $6.38, for a total value of $64,903.74. Following the sale, the chief executive officer directly owned 392,483 shares of the company’s stock, valued at approximately $2,504,041.54. This trade represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC increased its holdings in Lexeo Therapeutics by 370.0% in the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock worth $175,000 after acquiring an additional 39,627 shares in the last quarter. Millennium Management LLC raised its position in Lexeo Therapeutics by 654.8% during the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock worth $3,718,000 after acquiring an additional 929,538 shares during the period. Acadian Asset Management LLC purchased a new position in Lexeo Therapeutics during the first quarter valued at $85,000. Rhumbline Advisers grew its position in shares of Lexeo Therapeutics by 19.8% in the first quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock valued at $105,000 after purchasing an additional 4,995 shares during the period. Finally, Cerity Partners LLC acquired a new stake in shares of Lexeo Therapeutics in the second quarter valued at about $50,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.